SAB Biotherapeutics (SABS) Capital Expenditures (2021 - 2026)

SAB Biotherapeutics (SABS) has 5 years of Capital Expenditures data on file, last reported at $255376.0 in Q1 2026.

• Quarterly Capital Expenditures changed N/A year-over-year to $255376.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $463564.0 (changed N/A YoY) and the FY2025 annual result came in at $933156.0, up 176.69% from the prior year.
• Capital Expenditures grew to $255376.0 in Q1 2026, from $55377.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.4 million in Q1 2022 to a low of $21300.0 in Q1 2023.
• A 4-year average of $227400.5 and a median of $85306.0 in 2023 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures sank 98.43% — and 2024, when it jumped 505.98%.
• Tracing SABS's Capital Expenditures over 4 years: stood at $117754.0 in 2022, then tumbled by 42.37% to $67864.0 in 2023, then declined by 18.4% to $55377.0 in 2024, then surged by 361.16% to $255376.0 in 2026.
• The last three Capital Expenditures figures came in at $255376.0 (Q1 2026), $55377.0 (Q4 2024), and $100300.0 (Q3 2024), per Business Quant data.